Browsing: Stock

The race to reshape obesity and diabetes treatment is moving beyond weekly injections, and Vivani Medical’s long-acting GLP-1 implant has pushed that story into the spotlight. For investors, the question is how this kind of delivery shift might affect companies tied to GLP-1 drugs, devices, and support therapies. This article looks at 3 stocks from…

Kerry stock offers investors a way to participate in long-term global demand for taste, nutrition, and functional food ingredients. The Irish group Kerry Group plc (ISIN IE0004906560) has built a broad portfolio of technologies that support large food and beverage manufacturers as they respond to shifting consumer preferences, regulatory standards, and sustainability expectations. As a…

Viking Therapeutics has delivered a very large 5 year return, yet its current checks lean expensive, which raises questions about how much of the obesity drug opportunity is already reflected in the stock price

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 11.5% over the past six months, topping the S&P 500 by 4.3 percentage points

Eli Lilly shares remain near all-time highs as booming Mounjaro and Zepbound demand, global obesity-market growth, and bullish analyst targets keep the trillion-dollar pharma stock in focus

Kenvue stock represents exposure to one of the largest pure-play consumer health companies, with a portfolio spanning over-the-counter medicines, skincare and essential everyday products. As a standalone entity carved out from Johnson & Johnson, the company combines long-established brands, wide retail reach and a focus on categories that tend to be used regardless of the…

I don’t believe that Kailera (KLRA) represents yet another player chasing the likes of Novo Nordisk or Eli Lilly in obesity. Kailera is building a multi-modal obesity franchise. This means they are using human-validated assets

Levi Strauss & Co. (LEVI) stock dropped overnight even after the company topped fiscal second-quarter (Q2) expectations, with CEO Michelle Gass saying its shift toward becoming a denim lifestyle brand is driving growth across women’s apparel, digital channels and company-owned stores

BridgeBio Pharma BBIO is building its investment case around rare diseases where diagnosis, targeted treatment and commercial access are changing quickly

Eli Lilly’s shareholders are in store for even more gains, according to a respected investment bank